COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of 25-hydroxyvitamin D and a Structured Exercise Program on Dialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00798993
Recruitment Status : Completed
First Posted : November 27, 2008
Last Update Posted : June 10, 2013
Information provided by (Responsible Party):
Neil Boudville, Sir Charles Gairdner Hospital

Brief Summary:
This study aims to examine the effect of 25 hydroxyvitamin D supplementation and a structured exercise program on the exercise capacity and quality of life of haemodialysis patients with 25 hydroxyvitamin D insufficiency.

Condition or disease Intervention/treatment Phase
End Stage Kidney Disease Other: Structured Exercise program Drug: Cholecalciferol (25-Hydroxyvitamin D) Other: Usual exercise Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of 25-hydroxyvitamin D Supplementation and a Structured Exercise Program on Exercise Capacity and Quality of Life in Dialysis Patients
Study Start Date : January 2009
Actual Primary Completion Date : September 2011
Actual Study Completion Date : September 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Calcifediol

Arm Intervention/treatment
Active Comparator: Structured exercise program
Participants will be randomised at 3 months into either this group or the comparator of usual exercise.
Other: Structured Exercise program
30 minutes on an exercise bicycle during every dialysis

Experimental: Vitamin D
Cholecalciferol 2000U per day will be given to all participants for the duration of the study
Drug: Cholecalciferol (25-Hydroxyvitamin D)
Cholecalciferol 2000U per day will be given for duration of study to all participants

Placebo Comparator: Usual exercise
Participants randomised to this arm, at 3 months, will continue on their usual exercise routine
Other: Usual exercise
Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months

Primary Outcome Measures :
  1. Exercise capacity - modified shuttle walk test [ Time Frame: Basesline, 3 & 6 months ]

Secondary Outcome Measures :
  1. Quality of life with KDQOL [ Time Frame: Baseline, 3 & 6 months ]
  2. Quadriceps Strength [ Time Frame: Baseline, 3 & 6 months ]
  3. Serum phosphate [ Time Frame: baselibe, 3 & 6 months ]
  4. Feeling thermometer [ Time Frame: Baseline, 3 & 6 months ]
  5. Timed up and go [ Time Frame: baseline, 3 & 6 months ]
  6. Falls [ Time Frame: continuous ]
  7. Pulse wave velocity [ Time Frame: baseline, 3 & 6 months ]
  8. Bioimpedance [ Time Frame: Baseline, 3 & 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Stable on dialysis for at least 3 months
  2. Able to obtain informed consent
  3. Medically stable
  4. Dialysis adequacy at target for small solute clearance (ie Kt/V>1.2 or Urea reduction ratio>65%)
  5. Serum 25-hydroxyvitamin D levels less than 75nmol/L at baseline

Exclusion Criteria:

  1. Limb Amputation
  2. Impaired cognition
  3. Impaired vision
  4. Haemoglobin concentration < 110g/L
  5. Change in Erythropoiesis stimulating agent dose over the last 2 months
  6. Unable or unwilling to comply with exercise program

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00798993

Layout table for location information
Australia, Western Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia, 6009
Sponsors and Collaborators
Sir Charles Gairdner Hospital
Layout table for investigator information
Principal Investigator: Ben Bull Sir Charles Gairdner Hospital
Study Director: Neil Boudville Sir Charles Gairdner Hospital
Layout table for additonal information
Responsible Party: Neil Boudville, Associate Professor, Sir Charles Gairdner Hospital Identifier: NCT00798993    
Other Study ID Numbers: SCGH25OHD2008
First Posted: November 27, 2008    Key Record Dates
Last Update Posted: June 10, 2013
Last Verified: June 2013
Keywords provided by Neil Boudville, Sir Charles Gairdner Hospital:
Chronic kidney failure
25 hydroxyvitamin D
quadriceps strength
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Growth Substances
Bone Density Conservation Agents